NCT03511196View on ClinicalTrials.gov

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 17, 2018

Primary Completion Date

June 22, 2022

Study Completion Date

October 31, 2025

Conditions
Prostate CancerStage IV Prostate CancerAdvanced Prostate CancerAdenocarcinoma of the Prostate
Interventions
DRUG

Adaptive Androgen Deprivation Therapy (ADT)

ADT with Leuprolide, Goserelin, or Triptorelin, as GnRH agonist, every 4 weeks as outlined in study arm description.

DRUG

Abiraterone

Prednisone 5 mg once a day with food.

DRUG

Prednisone

Abiraterone 1000 mg daily with empty stomach.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

All Listed Sponsors
lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER